Kalytera Announces Initiation of Research Coverage by Echelon Wealth Partners
January 15 2019 - 7:30AM
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF)
(the "
Company" or "
Kalytera")
announced that Echelon Wealth Partners, Inc. (“Echelon”) has
initiated research coverage on Kalytera with a speculative "Buy"
rating and a one-year price target of $0.30 per share. The Company
is pleased with the report and the recommendation, but emphasizes
that the views expressed in the report are those of Echelon alone.
Echelon is a leading, independent Canadian-owned
and operated wealth management and capital markets firm.
Distribution and reproduction of the research report in any form is
solely at the discretion of Echelon.
About Kalytera
TherapeuticsKalytera Therapeutics, Inc. is pioneering the
development of CBD therapeutics. Through its proven leadership,
drug development expertise, and intellectual property portfolio,
Kalytera seeks to establish a leading position in the development
of CBD medicines for a range of important unmet medical needs, with
an initial focus on GVHD and treatment of acute and chronic
pain.
- Website Home: https://kalytera.co/
- News and Insights: https://kalytera.co/news/
- Investors: https://kalytera.co/investors/
Cautionary StatementsNeither
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
This press release may contain certain
forward-looking information and statements ("forward-looking
information") within the meaning of applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation in respect of its product candidate pipeline,
planned clinical trials, regulatory approval prospects,
intellectual property objectives and other statements containing
the words "believes", "anticipates", "plans", "intends", "will",
"should", "expects", "continue", "estimate", "forecasts" and other
similar expressions. Readers are cautioned to not place undue
reliance on forward-looking information. Actual results and
developments may differ materially from those contemplated by these
statements depending on, among other things, the risk that future
clinical studies may not proceed as expected or may produce
unfavourable results. Kalytera undertakes no obligation to comment
on analyses, expectations or statements made by third-parties, its
securities, or financial or operating results (as applicable).
Although Kalytera believes that the expectations reflected in
forward-looking information in this press release are reasonable,
such forward-looking information has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Kalytera's control. The forward-looking
information contained in this press release is expressly qualified
by this cautionary statement and is made as of the date hereof.
Kalytera disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise.
Contact Information
- Robert Farrell President, CEO (888) 861-2008
info@kalytera.co
Kalytera Therapeutics (TSXV:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kalytera Therapeutics (TSXV:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024